Montclair State University

Montclair State University Digital
Commons
Department of Mathematics Facuty Scholarship
and Creative Works

Department of Mathematics

9-1-2018

Cause and Consequence of Aβ
A – Lipid Interactions in Alzheimer
Disease Pathogenesis
Vijayaraghavan Rangachari
University of Southern Mississippi

Dexter N. Dean
Virginia Commonwealth University

Pratip Rana
Virginia Commonwealth University

Ashuwin Vaidya
Montclair State University, vaidyaa@mail.montclair.edu

Preetam Ghosh
Virginia Commonwealth University

Follow this and additional works at: https://digitalcommons.montclair.edu/mathsci-facpubs
Part of the Mathematics Commons

MSU Digital Commons Citation
Rangachari, Vijayaraghavan; Dean, Dexter N.; Rana, Pratip; Vaidya, Ashuwin; and Ghosh, Preetam, "Cause
and Consequence of Aβ – Lipid Interactions in Alzheimer Disease Pathogenesis" (2018). Department of
Mathematics Facuty Scholarship and Creative Works. 53.
https://digitalcommons.montclair.edu/mathsci-facpubs/53

This Review Article is brought to you for free and open access by the Department of Mathematics at Montclair
State University Digital Commons. It has been accepted for inclusion in Department of Mathematics Facuty
Scholarship and Creative Works by an authorized administrator of Montclair State University Digital Commons. For
more information, please contact digitalcommons@montclair.edu.

BBA - Biomembranes 1860 (2018) 1652–1662

Contents lists available at ScienceDirect

BBA - Biomembranes
journal homepage: www.elsevier.com/locate/bbamem

Cause and consequence of Aβ – Lipid interactions in Alzheimer disease
pathogenesis☆

T

⁎

Vijayaraghavan Rangacharia, , Dexter N. Deana, Pratip Ranab, Ashwin Vaidyac, Preetam Ghoshb
a

Department of Chemistry & Biochemistry, University of Southern Mississippi, Hattiesburg, MS 39406, USA
Department of Computer Science, Virginia Commonwealth University, Richmond, VA 23284, USA
c
Department of Mathematical Science, Montclair State University, Montclair, NJ 07043, USA
b

A R T I C LE I N FO

A B S T R A C T

Keywords:
Amyloid-beta
Surfactant
Membrane
Oligomer
Strain
Aggregation
Lipids

Self-templating propagation of protein aggregate conformations is increasingly becoming a signiﬁcant factor in
many neurological diseases. In Alzheimer disease (AD), intrinsically disordered amyloid-β (Aβ) peptides undergo
aggregation that is sensitive to environmental conditions. High-molecular weight aggregates of Aβ that form
insoluble ﬁbrils are deposited as senile plaques in AD brains. However, low-molecular weight aggregates called
soluble oligomers are known to be the primary toxic agents responsible for neuronal dysfunction. The aggregation process is highly stochastic involving both homotypic (Aβ-Aβ) and heterotypic (Aβ with interacting
partners) interactions. Two of the important members of interacting partners are membrane lipids and surfactants, to which Aβ shows a perpetual association. Aβ–membrane interactions have been widely investigated for
more than two decades, and this research has provided a wealth of information. Although this has greatly
enriched our understanding, the objective of this review is to consolidate the information from the literature that
collectively showcases the unique phenomenon of lipid-mediated Aβ oligomer generation, which has largely
remained inconspicuous. This is especially important because Aβ aggregate “strains” are increasingly becoming
relevant in light of the correlations between the structure of aggregates and AD phenotypes. Here, we will focus
on aspects of Aβ-lipid interactions speciﬁcally from the context of how lipid modulation generates a wide variety
of biophysically and biochemically distinct oligomer sub-types. This, we believe, will refocus our thinking on the
inﬂuence of lipids and open new approaches in delineating the mechanisms of AD pathogenesis. This article is
part of a Special Issue entitled: Protein Aggregation and Misfolding at the Cell Membrane Interface edited by
Ayyalusamy Ramamoorthy.

1. Aβ and Alzheimer disease pathology
Alzheimer disease (AD) is a fatal, progressive neurodegenerative
disorder with clinical manifestations that include acute memory loss,
cognitive decline and behavioral changes resulting in social inappropriateness. AD is the most common among all neurodegenerative
disorders, with over ﬁve million people aﬀected in the United States
alone [1]. Without medicinal intervention, this number is expected to
nearly triple by 2050 [1]. According to the US Centers for Disease
Control (CDC), the death rates from AD dramatically climbed to 55%
between 1999 and 2014, making viable diagnostic and therapeutic
avenues a critical need [2]. Discovered by the Bavarian psychiatrist
Alois Alzheimer in 1905, signiﬁcant advancements in understanding AD
only began to occur 7–8 decades later with the morphological understanding of two main pathological hallmark lesions in the AD brain:

extracellular neuritic plaques and intracellular neuroﬁbrillary tangles.
During the 1990s, it became clear that two proteins, amyloid-β (Aβ)
and hyperphosphorylated tau, are the major components of plaques and
tangles, respectively [3,4].
Aβ is generated by the proteolytic processing of amyloid precursor
protein (APP), which is abundant in the central nervous system but
ubiquitously expressed in many cell types [5,6]. APP is an integral
membrane protein containing a single transmembrane domain, and the
cleavage occurs sequentially by the aspartyl proteases, β- and γ-secretases (Fig. 1). While β-secretase cleaves APP on the extracellular side,
the γ-secretase complex hydrolyzes the protein within the transmembrane domain (Fig. 1). The γ-secretase complex comprises the proteins
Aph-1, presenelin-1 (PS1), presenelin-2 (PS2), and nicastrin, and has a
broader speciﬁcity in cleavage that leads to the generation of multiple
Aβ isoforms ranging from Aβ1–38 to Aβ1–43 [7]. The cleavage
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protein aggregation and amyloid formation in itself is an alternate
pathway during protein folding. In a typical aggregation pathway,
smaller oligomers are formed transiently along the ﬁbril formation
pathway that “roll down” the energy landscape towards energetically
favorable ﬁbrils. In reality, even within the energy landscape along the
“aggregation funnel” there are many diﬀerent pathways containing
several kinetic traps in which speciﬁc conformeric and structurally
variant species could be present. Indeed, it has become evident that
there are alternative pathways and kinetic traps along the aggregation
pathway [22,23], and that neurotoxic oligomers can also be populated
via such alternate pathways [24–27]. As mentioned earlier, the early
stages of aggregation (lag phase), being dominated by homotypic and
heterotypic stochastic interactions, could likely contain numerous kinetic traps. An obvious characteristic of such traps is that the oligomeric
aggregates that are formed may diﬀer in their conformation, degree of
aggregation (number of monomers within the assembly), heterogeneity,
or all of these factors. Such diﬀerences within these aggregates could
manifest in diﬀerences in their ability to seed the propagation of ﬁbrils.
Thus, depending on the number of such conformeric strains, ﬁbrils are
formed via diﬀerent pathways displaying structural heterogeneity and
polymorphism [28]. This has been further elaborated in the concluding
sub-section of this manuscript.
Fig. 1. Aβ generation by sequential protease cleavage involving β- and γ-secretases.

2.2. Aβ aggregate structure and AD phenotypes

speciﬁcity of the γ-secretase complex is also controlled by genetic
mutations in APP; however, the precise mechanism of the enzyme remains uncertain [8]. Among the isoforms, Aβ1–40 (Aβ40) is the predominant form followed by Aβ1–42 (Aβ42), but the latter is initially
observed in diﬀuse amyloid aggregates [9] and is believed to be responsible for early synaptic and neuronal dysfunction in AD brains.

Aβ aggregation is strongly driven by both homotypic (Aβ-Aβ) and
heterotypic (Aβ-solvent and/or Aβ-solute) interactions. Because of
stochasticity, the lag phase is highly susceptible to heterotypic interactions with other solutes present in the system. From years of research,
we have known that the Aβ “interactome” includes a variety of agents
such as metal ions [29,30], protein binding partners [31,32], natural
products and metabolites [33–37], as well as lipids and surfactants (as
elaborated in this article). Therefore, heterotypic interactions with any
Aβ interactome molecules have the potential to change the conformation of Aβ during the lag phase and alter the pathway of aggregation,
which could result in multiple conformational variants of aggregates
with distinct biochemical and cellular properties. Manifestations of
conformational and morphological diﬀerences in cellular toxicity have
been established in the past [38,39]. The signiﬁcance of Aβ ﬁbril
structure and morphology in AD is becoming far more critical than
originally thought. Somewhat similar to the observations in prion diseases [40,41], structure-to-phenotype correlations are beginning to
emerge. Recently, using brain-derived ﬁbrils as seeds, the Tycko laboratory has elegantly established that clinical phenotypic diﬀerences,
especially those leading to rapid-onset AD (rAD), could emerge in part
from the structure and morphology of the propagating ﬁbrils [42,43].
Along similar lines, Cohen et al. have reported conformationally-distinct Aβ aggregates in rAD cases as compared with typical AD [44]. In
recent reports by the Jucker and Prusiner laboratories, the authors revealed structural variations in etiological subtypes of AD brains on the
basis of their ability to bind ﬂuorescent probes [45,46]. Prion-like
propagation of Aβ has now been well understood from the demonstration that intracerebral injection of endogenous Aβ seeds induces
widespread deposition of Aβ in transgenic mice [47–53]. Inoculations
in such experiments either used Aβ-laden brain homogenates or exogenous ﬁbrils as seeds, and therefore, structural diversity of ﬁbril seeds
has mainly been attributed to propagation behavior of the seeds
[51,54,55].

2. Aggregation of Aβ and signiﬁcance of pathways
2.1. Spatiotemporal proﬁle of Aβ aggregation
Upon cleavage from APP by aspartyl proteases, Aβ peptide is mainly
released from the membrane into the extracellular matrix. The newly
generated Aβ is intrinsically disordered, which is reﬂected in its random
coil conformation [10–12]. The monomeric Aβ is highly susceptible to
aggregating with other Aβ molecules, and does so almost spontaneously
upon its generation from APP. Aggregation of Aβ is a nucleation-dependent process that follows a sigmoidal growth kinetics with the formation of a critical mass of aggregates called nucleus, being obligatory
for the emergence of mature ﬁbrils (Fig. 2). A schematic of homotypic
Aβ aggregation shows three broadly-deﬁned phases of aggregation,
namely a lag phase (I), growth phase (II) and a saturation phase (III)
(Fig. 2). The lag phase of aggregation is perhaps the most important
phase during aggregation from a physiological perspective, as elaborated later in this manuscript, and is mechanistically the most confounding of all the phases. Although there is consensus regarding the
formation of a nucleus during the lag phase, uncertainty remains about
the nature of nucleus; whether it is heterogeneous or homogenous [13],
or whether there is a single nucleation event or multiple events
[14–17]. In sum, one could describe the lag phase of aggregation as
being in dynamic ﬂux dominated by stochastic interactions between Aβ
conformeric ensembles until an ordered, relatively stable nucleus (or
nuclei) is (are) formed. Once the prerequisite and a critical aggregate
size is achieved (I in Fig. 2), the propagation phase ensues with forward
rates involving predominantly aggregate – monomer interactions that
result in an exponential increase in the rates of aggregation towards
high molecular weight protoﬁbrils (II in Fig. 2), which then form insoluble ﬁbrils in the saturation phase (III in Fig. 2) [18,19].
This aggregation mechanism, although consistent with numerous
reports, does not represent the complete picture of the aggregation
landscape. As previously described by Radford and others [20,21],

3. Lipids and membranes could be important members of the Aβ
interactome
The main focus of this review is to bring forth how lipids and surfactants are able to modulate the aggregation behavior of Aβ to generate a multitude of structurally and functionally diﬀerent aggregates
depending on the physiochemical nature of the surfactant. The aﬃnity
1653
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Fig. 2. Protein sequence of Aβ1–42 protein (a) and schematic of aggregation reaction involving pure homotypic (Aβ-Aβ) interactions.

conformation [67]. The two regions are separated by a kink, which is
signiﬁcant in membrane insertion [67]. Molecular dynamics (MD) simulations to model the interactions between Aβ oligomers and membranes showed formation of ion channels with two diﬀerent topologies,
suggesting a modulatory eﬀect of the membranes on Aβ structure and
conformation. More importantly, Aβ oligomers have now been widely
understood to form pores in both synthetic as well as cellular membranes, capable of generating conductance and classical channel activity [64,68,69]. Both Aβ monomers reconstituted with lipids as well
as pre-formed oligomers deposited on to synthetic or brain-derived lipids formed channels [70,71]. In addition, experimental observation of
the eﬀect of this channel on Ca2+ selectivity was supported by such
models [72,73]. Another study using MD simulations on Aβ42 peptide
monomers and oligomers identiﬁed insertion into the lipid bilayer in
agreement with other reports [74]. These theoretical results were also
consistent with the experimental observation that Aβ forms a cation
selective channel in both synthetic lipid-bilayers [75] and cellular
membranes [76]. However, it remains unknown whether the all oligomers are able to form channels in the membrane, and whether oligomer conformation capable of pore formation is induced by the interaction with lipid surfaces, which that precedes it. Such is the case
with zwitterionic lipids, to which a conserved region (K16-E22) within
the central region of Aβ bound to lipid surface prior to surface-catalyzed Aβ ﬁbril formation and transmembrane pore formation [77].

of Aβ peptides for membranes becomes obvious when one looks at the
generation of the peptides, as described above. The C-terminal sequence
of Aβ within APP is buried in the phospholipid bilayer, while the Nterminal remains outside. This is reﬂected in the sequence of the peptide with the N-terminal side of the peptide containing many polar
amino acids and the C-terminus containing a majority of hydrophobic
residues (Fig. 2). The amphipathic nature of Aβ peptides uniquely
presents itself to preferential interactions with interfaces such as liquidgaseous (water-air), liquid-solid (solvent-surface) and liquid-liquid
(phase separated). In this context, there is a high likelihood of amphipathic lipids and other surfactants to interact with Aβ by providing a
template for aggregation. When Aβ is released as a soluble monomer,
charged membranes act as two-dimensional aggregation-templates to
initiate accumulation of surface-associated Aβ, typically to augment
aggregation into neurotoxic structures [56].
4. Interaction and modulation of Aβ aggregation by lipids
4.1. Interactions with bilayer-forming lipids
A wealth of information has been generated from over two decades
of research on the interactions of Aβ with membrane surfactants. The
amphipathic Aβ peptide shows strong aﬃnity for membranes, and such
heterotypic interactions may aﬀect early steps of Aβ aggregation signiﬁcantly [57–62]. First, we will focus on the surfactants (lipids) containing two fatty acid acyl chains that predominantly form a lipid bilayer. In pathological contexts, lipid membranes, sub-cellular organelle
surfaces, synaptic vesicles, lipid rafts as well as endo- and exosomes can
signiﬁcantly aﬀect Aβ aggregation by accelerating and nucleating ﬁbril
formation, generating and stabilizing speciﬁc oligomers and even promoting polymorphic aggregates.

4.1.2. Interactions on lipid surfaces
Interactions of Aβ with lipid surfaces have been investigated by
using many diﬀerent models including solid support, self-assembled
monolayers, and membrane-mimics [78–80]. Many reports indicate
that Aβ interactions with the anionic phospholipids on reconstituted
liposomes and unilamillar vesicles are largely limited to the lipid surface at neutral pH [58,81,82]. In one report, anionic phospholipids
increased the ﬁbrillation of Aβ, while neutral, zwitterionic, and lipids
lacking phosphate groups did not show signiﬁcant eﬀect on Aβ ﬁbrillation rates [83]. Investigation into the eﬀects of surface charges on
Aβ aggregation using zwitterionic (2-dioleoylphosphatidylcholine
(DPPC) or 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC)), anionic
(1,2-dioleoyl-sn-glycero-3–[phospho-rac-(3-lysyl(1-glycerol))] (DOPG))
and cationic (1,2-dioleoyl-sn-glycero-3-methylammonium-propane
(DOTAP)) lipids led to the ﬁnding that Aβ aggregated in zwitterionic
DPPC and anionic DOPG, while it inserted and disrupted the membranes of cationic DOTAP and zwitterionic DOPC [84]. In one report,

4.1.1. Interactions leading to pore formation and membrane disruption
One of the widely investigated phenomena of Aβ-membrane interactions is the insertion of Aβ into the membranes and subsequent disruption. Importantly, Aβ has been long known to form Ca(II) permeable
channels in the membrane [63,64]. Association of Aβ with anionic lipid
monolayers has been observed leading to partial insertion of Aβ into the
membrane [65]. Such an interaction consequently promotes aggregation to Aβ ﬁbrils [66]. Investigation of such mechanisms by Aβ40 using
NMR spectroscopy indicated that the N-terminal region is unstructured
while the C-terminal hydrophobic region adopts an α-helical
1654
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also demonstrated the eﬀects of SDS on Aβ42 aggregation, which was
dependent on SDS concentration [99]. However, unlike Aβ40, within a
narrow range of SDS concentrations, soluble Aβ42 oligomers were
formed along a pathway diﬀerent from ﬁbril formation, which was
strictly dependent on the CMC of SDS [99]. This observation parallels
the one on well-characterized, 60 kDa “Aβ globulomers” which are also
formed along a pathway that is independent of the ﬁbril formation
pathway [100,101]. It is noteworthy that globulomers are generated in
the presence of 0.2% SDS, which is close to its CMC. Moreover, globulomers are shown to be neurotoxic by speciﬁcally blocking long-term
potentiation in rat hippocampal slices [100]. Characterization of SDSderived oﬀ-pathway oligomers showed a unique structure by NMR
spectroscopy [102,103]. Studies using DHPCs as micellar surfactants
also showed modulation of aggregation based on their CMCs - enhancement of ﬁbril formation was observed at submicellar concentrations (below CMC), while micellar concentrations (above CMC) stabilize Aβ in an α-helical conformation [104]. Non-esteriﬁed fatty acids
(NEFAs) have been used as model surfactants to investigate their eﬀects
on Aβ42 aggregation. Similar to those observed with SDS, NEFAs also
induce concentration-dependent eﬀects on Aβ. Three broadly categorized regimes based on the respective CMCs of NEFAs such as below,
near and above CMC, either augmented or inhibited Aβ42 aggregation
[105]. Only at near and above the CMCs did NEFAs induce oligomers of
Aβ42 via alternative pathways, while enhancement of ﬁbril formation
was observed below the CMC [105,106].

aggregation of Aβ on zwitterionic DOPC LUVs by FRET analysis indicated that the liposomes were able to catalyze ﬁbril formation via
secondary nucleation mechanisms involving aggregate fragmentation
[85]. This report also revealed that the binding on the lipid surface was
restricted to only aggregated Aβ and not the monomer, suggesting
secondary pathways induced by oligomeric forms of Aβ on the membrane surface. In negatively charged lipids, Aβ40 oligomer binding was
dependent on surface charges, while membrane insertion was dictated
by membrane rigidity, and both processes were clearly distinct [86].
MD simulations involving Aβ peptides and the phospholipid bilayer
using DPPC and dioleoyl phosphatidylserine (DOPS) vesicles showed
ﬁbril promotion on the surface of the membrane lipids because of the
peptide re-distribution on the surface via charged interactions, exhibiting an auto-regulation type behavior [87]. The interactions of Aβ
with membranes depend not only on the former's structure and conformational state, but also on reaction conditions. Good et al. observed
that Aβ-liposome interactions were higher for Aβ aggregates than
monomeric Aβ [88]. They found that Aβ aggregates bind to both cortical homogenates and membranes, whereas Aβ monomers bind to
homogenates only. However, another report using diﬀerent experimental conditions revealed that monomeric Aβ bound rapidly to liposomes, while the Aβ aggregates bind slowly [89]. An MD simulation
study on the interactions of a pre-formed Aβ42 tetramer on POPC
membranes showed that the tetramers were elongated, and changed
their overall structure upon interaction with the membrane surface
[90], suggesting that the membrane surface characteristics play an
important role in Aβ aggregate structure. Overall, these reports indicate
the surface characteristics of membranes, which are mainly dominated
by the lipid head groups, behave as speciﬁcity inducing factors for Aβ
oligomer conformations during aggregation.

4.3. Modulation of aggregation by lipids and membrane constituents
4.3.1. Evidence for lipid involvement in Aβ modulation
The eﬀects of Aβ interaction with lipids are diverse. Perhaps the
most signiﬁcant of them all is the ability of membrane lipids to modulate Aβ aggregation pathways in generating polymorphic aggregates
and many oligomer strains. Numerous reports over the last decade
using reconstituted phospholipid vesicles indicate formation of aggregates along oﬀ-ﬁbril forming pathways, paving a way for the generation of structurally-diverse oligomers [107–109]. Recently, Aβ42
aggregation on SUV and large unilamellar vesicles (LUV) from POPC
lipids showed formation of polymorphic aggregates with distinct biophysical characteristics [110]. In this study, LUVs with high POPC
concentrations suppressed amyloid formation that aﬀected ﬁbrillation
kinetics, as opposed to those with low POPC concentrations, demonstrating the eﬀect of concentration gradients along the liposome surface
in modulating aggregation pathways. To investigate the eﬀect of
membrane thickness on Aβ aggregation, Korshavn et al. used bilayers
formed by the short-chain 1,2-dilauroyl-sn-glycero-3-phosphocholine
(DLPC) lipid as a model for disease bilayers, while 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) as a model of normal bilayers [111].
They found that DLPC-assisted oligomers could disrupt the membranes
more eﬀectively than those generated from POPC vesicles, providing
evidence for the deleterious eﬀects of reduced membrane thickness. In
one report, zwitterionic lipid vesicles not only promoted Aβ42 aggregation, they did so by interacting speciﬁcally with the growing ﬁbrils, showing aggregate-speciﬁc interaction of these lipids [85]. Furthermore, these lipid vesicles were thought to augment monomerdependent secondary nucleation at the surface of existing ﬁbrils and
facilitate monomer-independent catalytic processes consistent with ﬁbril fragmentation and concomitant secondary aggregation pathways
[85]. In a diﬀerent study, it was also noted that Aβ aggregates formed
in solution could present a diﬀerent structure and toxicity upon interacting with the membranes [112]. It appears as though PG lipids
modify the aggregation process and induce toxic oligomers independently from the ﬁbrils along “oﬀ-pathways”, and their formation
is enhanced by the presence of OH groups on the membrane surface
[113]. In our laboratory, we have demonstrated the generation of oﬀpathway oligomers in the presence of NEFAs, which show distinct
biophysical and pathological properties from on-pathway ﬁbrils

4.2. Interactions of Aβ with micelle-forming lipids
As a rule of thumb, lipids containing a single acyl chain tend to form
micelles as opposed to a bilayer. Similar to the liposomal systems, micelles as membrane-mimicking environments have also provided a
wealth of information on a mechanistic understanding of Aβ – lipid
interactions. Anionic surfactants such as sodium dodecylsulfate (SDS),
often used as denaturants, have been used as model polar-nonpolar
interfaces to investigate the aggregation of Aβ and other amyloid proteins [67,91–95]. Yamamoto and colleagues investigated the eﬀect of
neutral, zwitterionic and anionic surfactants on Aβ aggregation and
found that all three surfactants were able to augment Aβ40 and Aβ42
aggregation in a concentration-dependent manner [92]. The eﬀects of
surfactants on the two peptides varied, with Aβ42 showing more pronounced aggregation than Aβ40. More importantly, the aggregation
behavior of the peptides showed strong dependence on surfactant
concentration. Only in a narrow range of concentrations below its critical micelle concentration (CMC), SDS was able to augment Aβ42 aggregation without any observable lag time [92]. Based on the idea that
micellar interfaces uniquely aﬀect Aβ aggregation, Nichols and coworkers demonstrated the phenomena of interfacial aggregation using
model interfaces composed of dilute hexaﬂuoro isopropanol (HFIP) as
well as buﬀer-chloroform [96,97]. They elegantly showed that Aβ aggregation is preferentially augmented at the polar – non-polar interfaces. Similar to Yamamoto and co-workers, Rangachari et al. also demonstrated that SDS accelerates Aβ40 aggregation in a concentrationdependent manner and compared the similarities to aggregates formed
in HFIP interfaces [93]. While near-CMC SDS promoted β-sheet conformations and ﬁbrillar aggregates, micellar SDS above the CMC stabilized Aβ40 in an α-helical conformation. Furthermore, near the CMC,
Aβ40 initially adopted an α-helical conformation corresponding to
amorphous oligomers, which eventually converted into β-sheet ﬁbrils
over time. Similar structural transitions from α-helix to β-sheet with a
concomitant increase in ﬁbril formation were also observed with Aβ40
in the presence of DPC surfactants [98]. Rangachari and co-workers
1655
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ﬁbril formation (on) and oligomer formation (oﬀ). The oﬀ-pathway
considers structurally diﬀerent monomers (formed by membrane/lipid
interactions) that proceed to form higher molecular weight oligomers
that are structurally diﬀerent from their on-pathway counterparts. This
study elegantly demonstrated the see-saw eﬀect of two mutually competing pathways, laying a foundation for simulating such dynamics in
Aβ aggregation. Friedman et al. modeled dynamics of amphipathic
peptide aggregation in the presence of surfactants [132]. They showed
that there are two speciﬁc states, aggregation prone and aggregation
protected, which correlate with the extent of aggregation. This work
further supports the premise that by altering surfactant to peptide ratio
one could generate diﬀerent aggregates. Recently, our work on Aβ –
NEFA interactions considers a modiﬁcation of the Powers' model to
incorporate the eﬀects of fatty acids on ﬁbril formation and oﬀ-pathway
micellar dynamics [117]. In this work, the combined on-pathway and
oﬀ-pathway dynamics were modeled. The models from these computations establish a competition between the on- and oﬀ-pathway reactions with the outcome of aggregation pathway clearly dependent upon
the surfactant concentration and phase transitions [117].

[114–116]. We have also shown that the aggregation pathway is dependent on the surfactant-Aβ ratio [105,117]. Thus, given the mobility
of cell membranes and lipid rafts in cellular environments, because of
which charge concentration variations develop along the cell surface, it
is highly likely that such surfactant interfaces are able to induce similar
eﬀects on Aβ aggregation. Some of the aforementioned reports establish
the fact that the physicochemical composition and concentration of the
membranes lead to diﬀerent speciﬁcities of interaction among Aβ aggregates, and promote aggregation in various ways. The data also
suggest that oligomers formed along oﬀ-ﬁbril formation pathways,
which may structurally diﬀer from their on-pathway counterparts,
could exhibit diﬀerent interaction regimes with the membrane.
Modulatory eﬀects were also observed for physiological lipids derived from endogenous sources. First, toxic oligomeric Aβ has been
observed in patients with AD [118], HCHWA-D [119], and after fatal
head injury [120] were found to be associated with membrane lipids as
complexes, suggesting a strong interaction between Aβ oligomers and
lipids. Aβ deposition in a form bound to plasma membranes resulted in
the formation of non-ﬁbrillar diﬀuse aggregates [121]. In their investigation into the interactions of Aβ with GM1-containing liposomes,
Hayashi and co-workers observed that Aβ peptides showed altered
aggregation kinetics with detectable protoﬁbrils [57]. They concluded
that this is due to the altered conformation adopted by Aβ in the presence of liposomes, which drives the aggregation into an alternate
pathway. Aβ42 interactions with brain-derived lipids also resulted in an
exclusive formation of small aggregates without any ﬁbrils, suggesting
generation and stabilization of oﬀ-pathway oligomers. A similar observation was also made with the co-incubation of Aβ with lipid rafts
isolated from brain tissues in which a rapid formation of tetrameric Aβ
was identiﬁed without the appearance of ﬁbrils even after long incubation times, indicating the generation and stabilization of oligomers
potentially as an oﬀ-pathway species [122].

4.3.3. Membrane components involved in the modulation of Aβ aggregation
Despite the establishment of possible alternative pathways of aggregation and stabilization of oligomers, it remains unclear what molecular factors precisely control Aβ to adopt multiple aggregation
pathways. However, many reports do suggest several key players that
may play a role in the modulation of aggregation. An early report on Aβ
aggregation in the presence of diﬀerent sub-cellular organelle membranes showed accelerated ﬁbril formation by endosomal and lysosomal membranes while it was inhibited by Golgi membranes, which
promoted oligomers exclusively [133]. This report brought out the fact
that lipid constitution could be key in dynamic regulation of Aβ aggregation pathways. In another report, the investigators show that the
presence of cholesterol within membranes inﬂuences the membrane
ﬂuidity, which in turn could control the outcome of their interactions
with Aβ leading to the adoption of alternate aggregation pathways and
polymorphic aggregates [134]. Several other reports have indicated
both GM1 and cholesterol as key factors aﬀecting the Aβ ﬁbrillation on
membranes. Aβ is known to recognize cholesterol-dependent clusters of
GM1-containing liposomes [135], and aggregation kinetics and pathways are found to be strictly controlled by cholesterol and ganglioside
amounts within the liposomes [58]. Although the nature of GM1
ganglioside interaction with Aβ remains controversial, the involvement
of GM1 gangliosides in Aβ aggregation was unambiguously established
when pretreatment of brain-derived GM1-containing liposomes with
CTxB, a GM1 ligand, showed inhibition of Aβ ﬁbrillation [136]. Furthermore, liposome-containing clusters of highly dense GM1 transformed Aβ into toxic oligomers without noticeable ﬁbrils, indicate the
modulatory eﬀects of GM1 on Aβ aggregation [137–140]. In a MD simulation study, GM1 interactions with Aβ and POPC and palmitoyloleoyl-phosphatidyl ethanolamine (POPE) membranes lead to the release of Aβ from the membranes, further envisaging the diverse eﬀect
GM1 can cause on Aβ [141]. In addition, single molecule experiments
on live neuroblastoma cells showed that interaction of gangliosides
with Aβ42 led to the formation of at least two oligomeric forms with
distinct biophysical and structural diﬀerences that show diﬀerent cytotoxicities [140]. Mechanistically, ganglioside clusters seem to oﬀer a
unique platform at their hydrophobic/hydrophilic interface for binding
of Aβ molecules and conﬁning their spatial movements to promote
aggregation on the ganglioside clusters [142]. Furthermore, membrane
curvature also seems to play a role in modulating aggregation [143],
which parallels some of the observations on membrane rigidity and
ﬂuidity both as cause and consequence of Aβ interactions [144–146]. In
a recent review, Cebecauer et al. elegantly presented a unifying view on
the concentration-dependent modulatory eﬀects of gangliosides on Aβ
aggregation and oligomer formation [147]. Furthermore, simulations
also reveal and support experimental observations that chemical

4.3.2. Evidence of modulation based on temporal models
Modulation of aggregation pathways to populate both oligomers
and ﬁbrils was also observed using non-physiological models of anionic,
cationic and neutral surfactants, further emphasizing the potential role
of surfactants in the modulation of aggregation [123,124]. Fig. 3
summarizes the dynamics of Aβ-surfactant interactions reported earlier
[117]. One of the main signatures of oligomers formed along the oﬀﬁbril formation pathways is the temporal kinetics. “Oﬀ-pathway” aggregates tend to have a longer half-life and are slow in converting to
ﬁbrils because of their potential stabilization in kinetics traps (Fig. 4).
To gain insights into the formation and decay of such aggregates,
temporal modeling is necessary. Over the years, mathematical models
and simulations have provided some important insights into the complex temporal behavior of Aβ aggregation and modulation, but such
models largely remain sparse. Mathematical models have been applied
to simulate the kinetics of diﬀerent types of protein aggregation pathways including amyloid proteins [125–128]. Such models can be
broadly categorized into kinetic, empirical and their variants such as
the Finke-Watzky (F-W) kinetic model [129]. Unfortunately, very few
models have considered amyloid and lipid/membrane interactions and
their eﬀects in protein aggregation. In her paper, Murphy stated the
urgency and importance of such modeling approaches [130]: “Elucidation of the intricate kinetic interplay between amyloidogenesis and
membranes provides a challenge that will need to be addressed to
completely ascertain the role of membranes in amyloid disease pathology.” To our knowledge, the ﬁrst mathematical formulation to
consider temporal modulation of aggregation involving competition
between on- and oﬀ-pathway was presented by Powers et al. [131]. The
speciﬁc eﬀects of lipids/membranes on the structure of Aβ oligomers
were not studied in this work; however, the bulk eﬀects of lipids/
membranes on aggregation behavior were modeled through ﬁtting the
experimental data. In this model, the monomers were considered to
aggregate via two diﬀerent, mutually exclusive pathways involving
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Fig. 3. Schematic diagram showing modulation of Aβ aggregation pathways by micelle-forming lipids (adapted from [117]). Lipid and surfactants show dynamics involving three
categorized phases depending on their equilibrium concentrations: below critical micelle concentrations (CMC), they exist predominantly in the non-micellar form while at high CMC
they are present as micelles. Near their CMCs, they exist in unstable and dynamic “pseudo-micellar” form. Binding of Aβ to these forms could change the lipid phase-transition dynamics
that result in modulation of aggregation pathways distinctly.

composition of the membrane also aﬀects the Aβ-lipid interactions. For
example, low cholesterol content and increased membrane ﬂuidity results in partial Aβ membrane insertion, while at high cholesterol content, Aβ diﬀuses into a more rigid membrane resulting in higher Aβ
membrane associations [147]. In a separate study, Evengelisti et al
studied the cytotoxic eﬀects of protein oligomers on membranes and
came to the conclusion that toxicity not only depends on the nature of
oligomers but also on the chemical composition of the membranes that
they interact with [148]. The same principle seems to hold true for
other amyloid proteins including Aβ.

5. Consequence of Aβ-lipid interactions
5.1. Cellular toxicity
Three broadly categorized mechanisms of oligomer-induced neurotoxicity have been revealed by prior research [149]. a) Extracellular
Aβ aggregates can bind to various receptors leading to the activation of
signaling pathways. b) Aβ oligomers can form membrane pores or
channels [64] leading to cell death, known as the “channel hypothesis”
[150,151]. c) Oligomers can be transported within the cells to induce
dysfunction of mitochondria, lysosome and breakdown of other cellular
processes. While these mechanisms have been recently reviewed by
Kotler et al. and Kayed et al. [152] and [149], there are a few points
worth noting here. First, the receptor-mediated mechanism postulated
by many reports involving receptors such as advanced glycation end
(AGE) products, nerve growth factor (NGF), NMDA, and NF-κB, underscores the involvement and importance of structurally diverse oligomers in neurotoxicity. A report by Kourie et al. investigated over 100
channels formed by Aβ40, which could be grouped into one of four
categories based on conductance, kinetics, selectivity, and pharmacological properties of the pores [153]. This report showed that heterogeneity of Aβ can manifest in part to the pore forming structure of
aggregates and their toxicity. More recently Serra-Batiste and coworkers generated a 60 kDa oligomer of Aβ42 in high concentrations of

Fig. 4. Kinetic and thermodynamic proﬁles of Aβ aggregation pathways in the absence
(orange) and in the presence of (green) surfactants. a) Homotypic aggregation (Aβ-Aβ) in
the absence of any interacting partners such as lipids, typically displays a sigmoidal
growth curve (orange) with lag phase, growth phase and saturation (on-pathway).
Heterotypic aggregation (Aβ-surfactants) is signiﬁcantly altered (represented as dashed
lines along a green background) depending on the nature of lipids (oﬀ-pathway). Such
alteration of pathways leads to diﬀerent oligomer and ﬁbrils strains. b) Aggregation
funnel represented in terms of energy landscape for homotypic (orange) and heterotypic
(green) interactions.
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and are the very ﬁrst family of molecules to interact with Aβ mainly
because of their perpetual association. As detailed above, lipids and Aβ
can reciprocally aﬀect each other. While Aβ can aﬀect lipid structure
and cause membrane disruption, pore formation and damage, lipid
constitution and its physicochemical character can induce conformational changes to Aβ and catalyze the formation of diverse oligomers.
Being an IDP, the structural plasticity of monomeric Aβ, together with
its amphipathic character, makes it highly susceptible for structural
transitions and modiﬁcations by lipids with signiﬁcant physiological
consequences. Lipid-Aβ interactions have particularly become relevant
in light of the recent ﬁndings that similar to prions, polymorphic aggregates could behave as distinct strains in imparting phenotypic differences in AD brains [167]. The conformationally-distinct oligomers
seed Aβ aggregation by recruiting disordered monomers towards aggregates with speciﬁc morphology. One of the deﬁning events in the
generation of stable, structurally-distinct oligomer seeds during the
early stages of aggregation is the interaction of monomers with lipids.
As elaborated above, membranes play a crucial role in initial structural
transitions of Aβ. Depending on the nature of interactions between Aβ
and membranes, oligomer seed-dependent propagation of aggregates
towards various diﬀerent structural forms results in discrete, structurebased cellular responses.
We now can realign our ideas on how membranes and lipids could
inﬂuence the aggregation and consequently AD pathogenesis. As schematically shown in Fig. 4a, temporal evolution of purely homotypic Aβ
aggregation displays a sigmoidal growth curve (orange trace; Fig. 4a).
Depending on parameters such as charge distribution, phase transition,
rigidity, and hydropathy, surfactants can alter this temporal evolution
of aggregates either by augmenting or inhibiting it (dashed lines;
Fig. 4a). One obvious consequence of such eﬀects is the generation of
conformationally-changed aggregates, which may propagate their
structure in many ways leading to distinct strains. This phenomenon
could also be understood based on a thermodynamic perspective also as
shown in Fig. 4b. Here, the so called “aggregation funnel” in orange
represents purely homotypic Aβ aggregation without the inﬂuence of
surfactants. The introduction of heterotypic interactions changes the
free energy landscape to accommodate and direct many conformational
strains into deeper kinetic pits (green area; Fig. 4b). Scenarios by which
surfactant-mediated strains can be generated are schematically depicted in Fig. 5. Monomer interaction with diﬀerent surfactant composition and chemistry may lead to the formation of oligomer strains,
which can propagate into morphologically-distinct ﬁbril strains (Fig. 5).
Such strains could interact and propagate diﬀerently to generate a
multitude of strains with potentially diverse pathological eﬀects.
Keeping such a picture in mind, one can see a correlation between
dynamic changes in aggregation and diversity in cellular response of Aβ
aggregates. The diverse cellular eﬀects in turn emerge from diversity in
aggregate structures, vis-à-vis strains. Systematic structure-receptor
correlations are yet to be clearly established, which may provide a
much deeper understanding into the emergence of phenotypic diﬀerences from conformational strains. Nevertheless, as described above, a
careful analysis of the large volume of literature on Aβ-membrane interactions generated over 2–3 decades indicates a conspicuous pattern
involving a modulatory role and a catalytic role of surfactants in generating key oligomer strains. However, more needs to be done to ascertain unambiguously a clear cause-and-eﬀect role of surfactants on
phenotypic divergence in AD, which perhaps holds the fundamental
basis for all Aβ-related pathologies.

DPC micelles, which upon addition to lipid bilayers formed β-sheet rich
nanopores [154]. These oligomers were similar in size to the SDSgenerated Aβ globulomers, which have been shown to inhibit long-term
potentiation in hippocampal slices [100]. This reveals that lipids can
mediate the formation of pore-forming oligomers, which are implicated
in neurotoxicity. Another method by which Aβ induces toxicity is by
modulating membrane ﬂuidity and conductance. Increase of membrane
conductance by several diﬀerent soluble oligomers (and not monomers
or ﬁbrils) was reported, and occurred without the formation of pores
[155]. A report by Kremer et al. on membrane ﬂuidity changes during
Aβ aggregation revealed that aggregates, but not monomers, decreased
membrane ﬂuidity, the extent of which could be correlated to aggregate
growth [144], in agreement with other reports [156,157]. Vestergaard
et al. have investigated the eﬀect that Aβ aggregates have on modulating membrane morphology and fusion events, and revealed that
Aβ42 oligomers localize more closely than ﬁbrils to mediate fusion of
LUVs with GUVs [158]. Furthermore, Aβ42 oligomers have also been
shown to promote oxidative lipid damage [159] and disrupt membrane
integrity [111,113]. The C-terminal fragment (29–42) of Aβ has been
shown to form β-sheet aggregates in the presence of lipid bilayers (PC/
PE (2:1) SUVs), which induced cellular apoptosis by fragmenting DNA
and activating Caspase-3 in PC-12 cells [160]. Along similar lines,
Marzesco et al. have demonstrated the potency of membrane-associated
Aβ through inoculation in transgenic mice [161]. Work from Wang and
co-workers has shown that Aβ-induced toxicity can be reduced by inhibiting cholesterol and ganglioside synthesis in PC-12 cells [162].
Some of the aforementioned reports signify the roles of a wide variety
of oligomer assemblies with distinct conformations, which were generated under the inﬂuence of membrane lipids that manifest in a wide
variety of diﬀerent cellular responses depending oligomer structure.
5.2. Oligomer strains and phenotypic outcomes
A wave of recent research, driven by pathologic similarities between
prion diseases and AD [163], supports the hypothesis that corruptive
protein templating, or seeding, is a prime mover of disease propagation.
Although it is unclear whether AD is infectious as are prion diseases,
Aβ, like prions, can form polymorphic and polyfunctional strains [51].
Several lines of evidence collectively argue that aggregated Aβ in the
brain extract is critical for in vivo seeding and the phenotype of the
induced Aβ deposits mirrors that of the deposits in the extract, suggesting an Aβ-templating mechanism [48]. Indeed, a large body of work
has demonstrated that intracerebral injection of endogenous Aβ seeds
induces widespread deposition of Aβ in transgenic mice [47–53]. Inoculations in such experiments used either Aβ-laden brain homogenates
or exogenous ﬁbrils as seeds. Strain-speciﬁc propagation of aggregates
and their eventual physiopathological fates are starting to correlate
with the structure of the propagation units [164–167]. Recently, the
Tycko laboratory elegantly established that phenotype diﬀerences
could indeed emerge in part from Aβ ﬁbril structure and morphology by
propagating ﬁbrils using brain derived ﬁbrils as seeds [42,43]. However, correlation between oligomer strains and ﬁbril morphology vis-àvis phenotypes remains elusive. Heterogeneity and diversity among
oligomers, as well as the diﬃculty in their isolation as discrete units
has, to a large extent, impeded our understanding of oligomeric structures and their behavior. This is especially true in the context of diverse
strains generated in the presence of lipids, which remains largely unexplored. Other manifestations of oligomer strains may involve crosspropagation of other amyloidogenic proteins leading to exacerbation
and/or clinically observed co-pathological phenotypes [168–171].

Transparency document
6. Summary and perspectives
The Transparency document associated with this article can be
found, in the online version.

It has now been established that many interacting partners including lipids, metal ions, proteins and natural products inﬂuence the
structure and aggregation of Aβ. Lipids are perhaps the most important
1658

BBA - Biomembranes 1860 (2018) 1652–1662

V. Rangachari et al.

Fig. 5. Schematic representation of interactions between
Aβ and surfactants leading to strain generation. Based on
the many reports detailed in this manuscript, the interaction of Aβ monomers with lipids are initiated by the surface
interactions, which are dictated by the physicochemical
characteristics of lipid head groups and other molecule
present on the membrane surface. Various hexagonal
structures on the surface indicate this aspect. The hexagonal structures embedded in the membrane represent
cholesterol. Aβ undergoes conformational changes based on
the nature of the lipid which generates diﬀerent conformational oligomer strains (denoted here as diﬀerent
shapes of yellow structures). Each strain can propagate
their structures resulting in polymorphic ﬁbrils.
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